Study comparing the response of psoriasis to narrow-band UVB phototherapy in the morning and afternoo

Not Applicable

Suspended

• Conditions: Psoriasis; Skin and Connective Tissue Diseases

• Registration Number: ISRCTN18225522
• Lead Sponsor: ewcastle upon Tyne Hospitals NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-23
• Last Update Posted: 4 May 2020
• Study Completion: 2020-10-31

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. At least 18 years of age
2. Able to speak English
3. Able to provide written informed consent
4. Have chronic plaque psoriasis
5. Prescribed NbUVB phototherapy
6. Able and willing to attend the phototherapy department regularly

Exclusion Criteria

1. Able to control their psoriasis or already controlled by topical therapy
2. Pregnant
3. Significant sun exposure, sun-bed use or previous NbUVB within the last month or be planning significant sun exposure or sun-bed use in the next month
4. Previously taken, in the last three months any of the following: methotrexate, azathioprine, ciclosporin, biological therapy or systemic steroids for treatment of psoriasis
5. Previously taken, in the last month, any oral photosensitising medications, including: thiazide diuretics, antibiotics such as tetracyclines and quinolones, non-steroidal anti-inflammatory drugs, phenothiazines, retinoids, sulphonylureas, quinine and St John’s Wort
6. Also suffer from diseases where phototherapeutic treatment is contraindicated: xeroderma pigmentosum, lupus erythematosus
7. Work night-shifts
8. Diagnosed circadian rhythm disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of apoptosis in skin biopsies, measured by manual and automated counts of histology slides at 24 hours after irradiation with narrowband UVB light (day 3)

Secondary Outcome Measures

Name	Time	Method
<br> 1. Minimal erythema dose (that is, comparing the skin's sensitivity to UV in the am and pm) measured visually, in line with current clinical practice, with the aid of an erythema meter, at 24 hours after test irradiation (day 2))<br> 2. Salivary cortisol levels in patients with psoriasis and associated circadian rhythm dysfunction, measured by ELISA at the following timepoints on days 1, 2 and 3: waking, 0900, 1600, before sleep<br> 3. Urinary melatonin levels in patients with psoriasis and associated circadian rhythm dysfunction, measured by ELISA from an early morning urine sample on days 2 and 3<br> 4. Sleep quality measured by Pittsburgh Sleep Quality Index and Morningness-Eveningness Questionnaire at baseline<br> 5. Symptoms of anxiety and depression measured with the Dermatology Life Quality Index, Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 at baseline<br>